This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Silva, M. C. Articles by Charles Coombes, R. Search for Related Content PubMed PubMed Citation Articles by Silva, M. C. Articles by Charles Coombes, R.

Intratumoral Aromatase as a Prognostic Factor in Human Breast Carcinoma¹

St. George's Hospital Medical School, Tooting, London, S.W 17 OQT [M. C. S., R. C. C.]; Institute of Cancer Research, Sutton, Surrey SM2 5PS [M. G. R., B. G.]; Chelsea Hospital for Women, Chelsea, London, SW3 6LT [M. D.]; Royal Marsden Hospital, Fulham Road, London SW3 6JJ [J. A. M., I.F.], United Kingdom

Intratumoral aromatase activity (AA) was measured in 145 samples of human primary breast carcinoma using the tritiated water release assay which quantifies the tritium lost to water during the aromatization of 1ß-[³H]androstenedione to estrone. Significant AA was detected in 91/145 (63%) tumors. The possibility of a relationship between AA and a variety of clinical prognostic factors such as estrogen receptors, menopausal status, site, size, and histological grade of tumor was investigated. Possible relationship with time to relapse, overall survival, and survival of patients after relapse were also studied to determine whether intratumoral AA itself was of any prognostic value. There was no relationship between AA and tumor size, site, nodal status, menopausal status or estrogen receptors. However there was a significant correlation between AA and histological grade with an excess of AA-positive tumors having high grade (P = 0.03). There was no significant relationship between AA and overall survival (P > 0.1), but there was a marginal inverse correlation between AA and time to relapse (P < 0.1). A statistically significant correlation was found between AA and survival of patients after relapse (P < 0.05).

¹ This work was supported by a grant from the University of Amazonas and the Ministry of Education of Brazil (CAPES).

² To whom requests for reprints should be addressed, at Royal Marsden Hospital, Academic Surgical Unit, Fulham Road, London SW3 6JJ, UK.

Received 8/ 3/88. Revised 1/30/89. Accepted 2/13/89.

This article has been cited by other articles:

				K. Subbaramaiah, C. Hudis, S.-H. Chang, T. Hla, and A. J. Dannenberg EP2 and EP4 Receptors Regulate Aromatase Expression in Human Adipocytes and Breast Cancer Cells: EVIDENCE OF A BRCA1 AND p300 EXCHANGE J. Biol. Chem., February 8, 2008; 283(6): 3433 - 3444. [Abstract] [Full Text] [PDF]

				K. Subbaramaiah, L. R. Howe, E. R. Port, E. Brogi, J. Fishman, C. H. Liu, T. Hla, C. Hudis, and A. J. Dannenberg HER-2/neu Status Is a Determinant of Mammary Aromatase Activity In vivo: Evidence for a Cyclooxygenase-2-Dependent Mechanism. Cancer Res., May 15, 2006; 66(10): 5504 - 5511. [Abstract] [Full Text] [PDF]

				T. Suzuki, Y. Miki, Y. Nakamura, T. Moriya, K. Ito, N. Ohuchi, and H. Sasano Sex steroid-producing enzymes in human breast cancer Endocr. Relat. Cancer, December 1, 2005; 12(4): 701 - 720. [Abstract] [Full Text] [PDF]

				J. Geisler and P. E. Lonning Aromatase Inhibition: Translation into a Successful Therapeutic Approach Clin. Cancer Res., April 15, 2005; 11(8): 2809 - 2821. [Abstract] [Full Text] [PDF]

				M. J. Reed, A. Purohit, L. W. L. Woo, S. P. Newman, and B. V. L. Potter Steroid Sulfatase: Molecular Biology, Regulation, and Inhibition Endocr. Rev., April 1, 2005; 26(2): 171 - 202. [Abstract] [Full Text] [PDF]

				Y. Miyoshi, A. Ando, S. Hasegawa, M. Ishitobi, T. Taguchi, Y. Tamaki, and S. Noguchi High Expression of Steroid Sulfatase mRNA Predicts Poor Prognosis in Patients with Estrogen Receptor-positive Breast Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2288 - 2293. [Abstract] [Full Text] [PDF]

				H. Sasano and N. Harada Intratumoral Aromatase in Human Breast, Endometrial, and Ovarian Malignancies Endocr. Rev., October 1, 1998; 19(5): 593 - 607. [Abstract] [Full Text]